Platelet activation in subjects carrying factor V Leiden or factor II A20210 mutations [4]

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 11, 2006, Pages 2496-2498

  Grandone, E ^a   Martinelli, I ^b   Margaglione, M ^a,c   Dragani, A ^d   Davì, Giovanni ^e  

^a CASA SOLLIEVO DELLA SOFFERENZA HOSPITAL   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

^c UNIVERSITY OF FOGGIA   (Italy)

^d Ospedale Civile di Pescara   (Italy)

^e UNIVERSITY OF CHIETI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

11 OXOTHROMBOXANE B2; BLOOD CLOTTING FACTOR 5 LEIDEN; PROTHROMBIN; THROMBIN;

ADOLESCENT; ADULT; AGED; BLOOD SAMPLING; CONTROLLED STUDY; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HETEROZYGOSITY; HOMOZYGOSITY; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; PROSTAGLANDIN URINE LEVEL; PROTEIN BLOOD LEVEL; RADIOIMMUNOASSAY; SYMPTOMATOLOGY; THROMBOCYTE ACTIVATION; THROMBOPHILIA; URINALYSIS; VEIN PUNCTURE; VENOUS THROMBOEMBOLISM;

ADOLESCENT; ADULT; AGED; FACTOR V; FEMALE; HUMANS; MALE; MIDDLE AGED; MUTATION, MISSENSE; PLATELET ACTIVATION; PROTHROMBIN; RISK FACTORS; THROMBOEMBOLISM;

EID: 33750112855     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.02191.x     Document Type: Letter

References (21)

1. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factor V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-7.
2. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′-untranslated region of the prothrombin gene is associated with elevated prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
3. Martinelli I, Bucciarelli P, Margaglione M, De Stefano V, Castaman G, Mannucci PM. The risk of venous thromboembolism in family members with mutations in the genes of factor V or prothrombin or both. Br J Haematol 2000; 111: 1223-9.
4. Margaglione M, Brancaccio V, D'Andrea G, Cappucci G, Iannaccone V, Vecchione G, Grandone E, Di Minno G. Increased risk for thrombosis in carriers of the prothrombin G→A20210 gene variant. Ann Intern Med 1998; 129: 89-93.
5. Emmerich J, Rosendaal FR, Cattaneo M, Margaglione M, De Stefano V, Cumming T, Arruda V, Hillarp A, Reny JL. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism -pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost 2001; 86: 809-16.
6. Martinelli I, Bottasso B, Duca F, Faioni E, Mannucci PM. Heightened thrombin generation in individuals with resistance to activated protein C. Thromb Haemost 1996; 75: 703-5.
7. Zoller B, Holm J, Svensson P, Dahlbach B. Elevated levels of prothrombin activation fragment 1+2 in plasma from patients with heterozygous Arg506 to Gln mutation in the factor V gene (APC-resistance) and/or inherited protein S deficiency. Thromb Haemost 1996; 75: 270-4.
8. Simioni P, Scarano L, Gavasso S, Sardella C, Girolami B, Scudeller A, Girolami A. Prothrombin fragment 1+2 and thrombin-antithrombin complex levels in patients with inherited APC resistance due to factor V Leiden mutation. Br J Haematol 1996; 92: 435-41.
9. Kyrle PA, Mannhalter C, Beguin S, Stumphlen A, Hirschl M, Weltermann A, Stain M, Brenner G, Speiser W, Pabinger I, Lechner K, Eichinger S. Clinical studies and thrombin generation in patients homozygous or heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol 1998; 18: 1287-91.
10. Ferroni P, Basili S, Falco A, DavìG. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004; 2: 1282-91.
11. DavìG, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M, Nutini M, Sensi S, Patrono C. Platelet activation in obese women: Role of inflammation and oxidant stress. JAMA 2002; 288: 2008-14.
12. DavìG, Catalano I, Averna M, Notarbartolo A, Strano A, Ciabattoni G, Patrono C. Thromboxane biosythesis and platelet function in type II diabetes mellitus. N Engl J Med 1990; 322: 1769-74.
13. DavìG, Ganci A, Averna M, Giammaresi C, Barbagallo C, Catalano I, Cala A, Notarbartolo A. Thromboxane biosynthesis, neutrophil and coagulative activation in type IIa hypercholesterolemia. Thromb Haemost 1995; 74: 1015-9.
14. Gresele P, Catalano M, Giammarresi C, Volpato R, Termini R, Ciabattoni G, Nenci GG, DavìG. Platelet activation markers in patients with peripheral arterial disease: A prospective comparison of different platelet function tests. Thromb Haemost 1997; 78: 1434-7.
15. Ciabattoni G, Maclouf J, Catella F, FitzGerald GA, Patrono C. Radioimmunoassay of 11-dehydro-TXB 2 in human plasma and urine. Biochim Biophys Acta 1987; 918: 29-37.
16. Utsonomiya T, Krausz MM, Levine L, Sherpo D, Hetchman HD. Thromboxane mediation of cardiopulmonary effects of embolism. J Clin Invest 1982; 70: 361-8.
17. Cignarella A, Mussoni L, Mannucci L, Ferioli E, Puglisi L, Tremoli E. Platelet activation supports the development of venous thrombosis in hyperlipidemic rats. Blood Coagul Fibrinolysis 1998; 9: 47-53.
18. Ciabattoni G, Pugliese F, Davi G, Pierucci A, Simonetti BM, Patrono C. Fractional conversion of thromboxane B2 to urinary 11-dehydrothromboxane B2 in man. Biochim Biophys Acta 1989; 992: 66-70.
19. Patrono C, Ciabattoni G, Pugliese F, Pierucci A, Blair IA, FitzGerald GA.Estimated rate of thromboxane secretion into the circulation of normal humans. J Clin Invest 1986; 77: 590-4.
20. FitzGerald GA, Pedersen AK, Patrono C. Analysis of prostacyclin and thromboxane biosynthesis in cardiovascular disease. Circulation 1983; 67: 1174-7.
21. DavìG, Falco A, Patrono C. Determinants of F2-isoprostane biosynthesis and inhibition in man. Chem Phys Lipids 2004; 128: 149-63.